Takeda Pharmaceutical Company Limited (NYSE: TAK) is 3.40% higher on its value in year-to-date trading and has touched a low of $12.28 and a high of $16.30 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The TAK stock was last observed hovering at around $16.19 in the last trading session, with the day’s loss setting it -0.06% off its average median price target of $16.32 for the next 12 months. It is also 36.79% off the consensus price target high of $25.52 offered by 14 analysts, but current levels are -18.95% lower than the price target low of $13.56 for the same period.
Currently trading at $16.13, the stock is 2.51% and 7.44% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.62 million and changing -0.37% at the moment leaves the stock 13.89% off its SMA200. TAK registered 10.03% gain for a year compared to 6-month gain of 10.25%.
The stock witnessed a 4.74% loss in the last 1 month and extending the period to 3 months gives it a 27.21%, and is -0.12% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.08% over the week and 1.14% over the month.
Takeda Pharmaceutical Company Limited (TAK) has around 47347 employees, a market worth around $50.51B and $29.20B in sales. Current P/E ratio is 30.26. Profit margin for the company is 5.70%. Distance from 52-week low is 31.35% and -1.04% from its 52-week high. The company has generated returns on investments over the last 12 months (3.90%).
Takeda Pharmaceutical Company Limited (TAK) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Takeda Pharmaceutical Company Limited (TAK) is a “Overweight”. 14 analysts offering their recommendations for the stock have an average rating of 2.70, where 7 rate it as a Hold and 1 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Takeda Pharmaceutical Company Limited is expected to release its quarterly report on 05/11/2023.The EPS is expected to shrink by -39.00% this year.
Takeda Pharmaceutical Company Limited (TAK) Top Institutional Holders
The shares outstanding are 3.10B, and float is at 3.07B with Short Float at 0.24%.
Takeda Pharmaceutical Company Limited (TAK): Who are the competitors?
The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading 2.09% up over the past 12 months and Sanofi (SNY) that is -4.78% lower over the same period. Pfizer Inc. (PFE) is -15.31% down on the 1-year trading charts.